Volume 11, Number 4—April 2005
Dispatch
Ross River Virus Disease Reemergence, Fiji, 2003–2004
Philipp Klapsing*†, J. Dick MacLean*
, Sarah Glaze‡, Karen L. McClean‡, Michael A. Drebot§, Robert S. Lanciotti¶, and Grant L. Campbell¶
, Sarah Glaze‡, Karen L. McClean‡, Michael A. Drebot§, Robert S. Lanciotti¶, and Grant L. Campbell¶Table
Results of tests of patients’ serum for antibodies to selected alphaviruses*
| IgM results† |
PRNT titers‡ |
|||||
|---|---|---|---|---|---|---|
| Patient | Interval (d)§ | RRV | BFV | RRV | BFV | SINV |
| 1 | 10 | Positive | Negative | 320 | <10 | <10 |
| 21 | Positive | Negative | 1,280 | <10 | <10 | |
| 141 | Equivocal | Negative | 160 | ND | ND | |
| 2 | 16 | Positive | Negative | 5,120 | <10 | ND |
| 33 | Positive | Negative | 5,120 | <10 | ND | |
*Ig, immunoglobulin; PRNT, plaque-reduction neutralization test; RRV, Ross River virus; BFV, Barmah Forest virus; SINV, Sindbis virus; ND, not done.
†IgM-capture enzyme immunoassay; samples tested at 1:400 dilution; positive samples had a positive-to-negative (P/N) absorbance ratio >3.0; equivocal samples had a P/N ratio 2.0–3.0 (10); no test for anti-SINV IgM was available.
‡90% plaque-reduction endpoints; >10 is considered positive (11).
§From onset of illness to serum collection.
